UK markets closed
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • FTSE 250

    22,775.28
    +283.92 (+1.26%)
     
  • AIM

    1,262.60
    +9.91 (+0.79%)
     
  • GBP/EUR

    1.1495
    -0.0015 (-0.13%)
     
  • GBP/USD

    1.3990
    +0.0098 (+0.70%)
     
  • BTC-GBP

    42,058.04
    +975.55 (+2.37%)
     
  • CMC Crypto 200

    1,480.07
    +44.28 (+3.08%)
     
  • S&P 500

    4,232.60
    +30.98 (+0.74%)
     
  • DOW

    34,777.76
    +229.23 (+0.66%)
     
  • CRUDE OIL

    64.82
    +0.11 (+0.17%)
     
  • GOLD FUTURES

    1,832.00
    +16.30 (+0.90%)
     
  • NIKKEI 225

    29,357.82
    +26.45 (+0.09%)
     
  • HANG SENG

    28,610.65
    -26.81 (-0.09%)
     
  • DAX

    15,399.65
    +202.91 (+1.34%)
     
  • CAC 40

    6,385.51
    +28.42 (+0.45%)
     

Non-Viral Drug Delivery Systems Market by Type of Molecule and Key Geographies : Industry Trends and Global Forecasts, 2021-2030

ReportLinker
·9-min read

INTRODUCTION Over time, advances in molecular biology and pharmacological chemistry have enabled the identification of biological targets localized in the subcellular space, and development of therapeutic leads against them.

New York, April 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Non-Viral Drug Delivery Systems Market by Type of Molecule and Key Geographies : Industry Trends and Global Forecasts, 2021-2030" - https://www.reportlinker.com/p06064555/?utm_source=GNW
In fact, there are several clinical conditions, which were previously considered undruggable since the traditional small molecule-based interventions were unable to penetrate the selectively permeable cell membrane. Presently, there are many biopharmaceuticals interventions that are designed to bind to intracellular proteinaceous entities responsible for causing a number of diseases. Given the limited targeting capabilities of small molecule drugs (experts estimate that such therapeutics can selectively bind to only 10% of the human genome), biologics, especially nucleic acid-based therapies represent the future of pharmacology. Interestingly, most biotherapeutics need to penetrate the cell membrane in order to mediate their therapeutic effects. Considering the fact that over 20% of the proteome, which includes a large number of viable therapeutic targets, is localized within the cell membrane, the need to facilitate the intracellular delivery of several novel drugs / therapies is considered to be one of the major challenges within the modern pharmaceutical industry.

Over time, medical researchers have developed a variety of virus-based and non-viral strategies to facilitate the entry of pharmacological molecules into the cytosol. Examples include cell penetrating peptides (CPP), DNA-dependent technologies, exosome-based drug delivery systems and nanoparticles based mechanisms. Recently, there was a surge in the demand for intracellular drug delivery solutions for multiple mRNA based therapeutic and preventive interventions being developed against COVID-19. In fact, the vaccines developed by Moderna and Pfizer / BioNTech use lipid nanoparticles to facilitate the intracellular delivery of their respective mRNA payloads. In the recent past, various technology developers have forged strategic alliances with therapy developers to support the development of drug formulations that can be targeted to the intracellular space. Given the growing demand for interventions that require cell internalization, the intracellular drug delivery technologies market is poised to witness substantial growth in the foreseen future.

SCOPE OF THE REPORT
The “Non-Viral Drug Delivery Systems: Focus on Intracellular Technologies and Intracellular Biologics Market, 2021-2030” report features an extensive study of the current landscape and the likely future opportunities in intracellular drug delivery technologies market for the next 10 years. Amongst other elements, the report includes:
A detailed review of the overall landscape of the intracellular drug delivery technologies, featuring an in-depth analysis based on a number of parameters, such as type of molecule delivered, type of biologic delivered, type of bond between the vehicle and the payload, type of vehicle used, and availability of intellectual property. In addition, the chapter features a list of technology developers and a detailed analysis based on year of establishment, company size and geographical location.
A detailed competitiveness analysis of intracellular drug delivery technologies, taking into consideration the supplier power (based on the year of establishment of the developer) and key technology specifications, such as availability of intellectual property, number of deals signed during 2015 - 2020, number of products / programs developed based on technologies and type of molecule(s) delivered (biologics / small molecules).
An in-depth analysis of the patents filed for intracellular drug delivery technologies based on various relevant parameters, such as publication year, geographical location, issuing authority, assigned CPC symbol, highlighting the emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (specific to technology platforms), product development and commercialization agreements, manufacturing agreements, mergers and acquisitions, and other relevant agreements.
Elaborate profiles of prominent technology developers engaged in this domain. Each profile features a brief overview of the company, its financial information (if available), information on its technology portfolio, recent developments and an informed future outlook.
A case study on the molecules developed / being developed using the intracellular drug delivery technology with analysis based on the phase of development, type of molecule and the target disease indication.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for intracellular drug delivery technologies. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2021-2030. The report features likely distribution of the current and forecasted opportunity across the [A] type of molecule delivered (DNA, RNA, small molecule and others), and [B] key geographical regions (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
Tehila Ben-Moshe, and Itay Friedman (Chief Executive Officer and Chief Scientific Officer, Biond Biologics)
Anders Høgset (Chief Scientific Officer, PCI Biotech)
Melissa Wagner (Senior Director, Business Development, SRI International)

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
Who are the leading players engaged in development of intracellular drug delivery technologies?
Which partnership models are commonly adopted by stakeholders engaged in this domain?
What type of molecule can be delivered using intracellular drug delivery technologies?
How is the intellectual property landscape likely to evolve in the foreseen future?
How is the current and future market opportunity likely to be distributed across key market segments and geographical region?

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the intracellular drug delivery technologies market and describes its evolution in the short-mid-term and long term.

Chapter 3 provides an introduction to the concept of intracellular drug delivery technologies. It highlights the need for targeted drug delivery and approaches used for intracellular drug delivery. In addition, it discusses the future perspectives of this segment of the pharmaceutical industry.

Chapter 4 provides an overview of the overall market landscape of intracellular drug delivery technologies, featuring a comprehensive list of technologies and analysis based on a number of parameters, such as type of molecule delivered, type of biologic delivered, type of bond between the vehicle and the payload, type of vehicle used, and information on intellectual property. It also includes a list of technology developers and a detailed analysis based on year of establishment, company size and geographical location.

Chapter 5 presents a detailed competitiveness analysis of intracellular drug delivery technologies, based on the supplier power (based on the year of establishment of developer company) and key technology specifications, such as (in alphabetical order) availability of intellectual property, number of deals signed during 2015-2020, number of products / programs developed based on technologies and type of molecule(s) delivered (biologics / small molecules).

Chapter 6 features detailed profiles of prominent technology developers in this domain. Each profile includes a brief overview of the company, its financial performance (if available), information on its technology portfolio, recent developments and a comprehensive future outlook.

Chapter 7 provides an in-depth analysis of patents filed for intracellular drug delivery technologies based on the parameters, such as publication year, geographical location, issuing authority and assigned CPC symbol, highlighting the emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 8 features an elaborate discussion of the various collaborations and partnerships that have been established in the recent past. It includes a brief description of various types of partnership models, such as R&D collaborations, licensing agreements (specific to technology platforms), product development and commercialization agreements, manufacturing agreements, and mergers and acquisitions. In addition, it includes a detailed analysis of partnerships, based on year of partnership, type of partnership, and regional activity.

Chapter 9 is a case study providing detailed insights on current market landscape of intracellular therapies developed using intracellular drug delivery technologies. In addition, it includes a detailed analysis of these therapies based on parameters, such as type of molecule, phase of development, target disease indication, therapeutic areas, route of administration and delivery technology used.

Chapter 10 presents an insightful market forecast analysis, highlighting likely growth of intracellular drug delivery technologies market till the year 2030, on the basis of likely licensing deal structures and agreements that are expected to be signed in the foreseen future. We have provided inputs on the likely distribution of the opportunity by type molecule (DNA, RNA, small molecules and others), and key geographical regions (North America, Europe, Asia Pacific and rest of the world).

Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the drug delivery technology industry.

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Anders Høgset (Chief Scientific Officer, PCI Biotech), Melissa Wagner (Senior Director, Business Development, SRI International), Tehila Ben-Moshe, and Itay Friedman (Chief Executive Officer and Chief Scientific Officer, Biond Biologics).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix, which contains a list of companies and organizations mentioned in this report.
Read the full report: https://www.reportlinker.com/p06064555/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001